NeoGenomics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- NeoGenomics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $893.00K, a 5.43% increase year-over-year.
- NeoGenomics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-03-31 was $909.00K, a 36.17% decline year-over-year.
- NeoGenomics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-09-30 was $851.00K, a 5.13% decline year-over-year.
- NeoGenomics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $847.00K, a 33.83% decline year-over-year.
- NeoGenomics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $3.78M, a 2.32% decline from fiscal 2024.
- NeoGenomics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $3.87M, a 5.77% increase from fiscal 2023.
- NeoGenomics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $3.66M, a 3.35% decline from fiscal 2022.
- NeoGenomics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $3.79M, a 13.14% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $893.00K 10-Q · filed 2026-07-28 | |
| 2026-03-31 | $909.00K 10-Q · filed 2026-07-28 | |
| 2025-12-31 | $3.78M 10-K · filed 2026-02-17 | |
| 2025-09-30 | $851.00K 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $847.00K 10-Q · filed 2026-07-28 | |
| 2025-03-31 | $1.42M 10-Q · filed 2026-07-28 | |
| 2024-12-31 | $3.87M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $897.00K 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $1.28M 10-Q · filed 2025-10-28 | |
| 2024-03-31 | $917.00K 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $3.66M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $863.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $1.03M 10-Q · filed 2024-11-05 | |
| 2023-03-31 | $811.00K 10-Q · filed 2024-11-05 | |
| 2022-12-31 | $3.79M 10-K · filed 2025-02-18 | |
| 2022-09-30 | $1.13M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $807.00K 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $971.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $4.36M 10-K · filed 2024-02-20 | |
| 2021-09-30 | $1.02M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $1.25M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $1.02M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $3.58M 10-K · filed 2023-02-24 | |
| 2020-09-30 | $808.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $928.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $796.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $2.33M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $564.00K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $653.00K 10-Q · filed 2020-10-29 | |
| 2019-03-31 | $419.00K 10-Q · filed 2020-10-29 | |
| 2018-12-31 | $1.05M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $267.00K 10-Q · filed 2019-11-13 | |
| 2018-06-30 | $231.00K 10-Q · filed 2019-11-13 | |
| 2018-03-31 | $267.00K 10-Q · filed 2019-11-13 | |
| 2017-12-31 | $844.00K 10-K · filed 2020-02-28 | |
| 2016-12-31 | $736.00K 10-K · filed 2019-02-26 | |
| 2015-12-31 | $369.00K 10-K · filed 2018-03-13 | |
| 2014-12-31 | $353.00K 10-K · filed 2017-03-14 | |
| 2013-12-31 | $230.00K 10-K · filed 2016-04-18 | |
| 2012-12-31 | $89.00K 10-K · filed 2015-03-03 | |
| 2011-12-31 | $153.00K 10-K · filed 2014-02-24 | |
| 2010-12-31 | $150.00K 10-K · filed 2012-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |